PMID- 25848360
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150407
LR  - 20220316
IS  - 1662-6575 (Print)
IS  - 1662-6575 (Electronic)
IS  - 1662-6575 (Linking)
VI  - 8
IP  - 1
DP  - 2015 Jan-Apr
TI  - A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in 
      a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone 
      Metastases.
PG  - 101-5
LID - 10.1159/000375119 [doi]
AB  - Breast cancer is one of the most frequently diagnosed cancers and a leading cause 
      of death in women worldwide. Despite significant advances in the treatment of 
      hormone receptor-positive breast cancer, tumor metastasis occurs frequently and 
      is associated with poor long-term prognosis. The mammalian target of rapamycin 
      (mTOR) pathway plays a central role in cancer cell growth, proliferation, and 
      resistance to endocrine therapies. Therefore, mTOR inhibitors such as everolimus 
      in combination with nonsteroidal aromatase inhibitors might reverse endocrine 
      resistance and improve clinical outcomes in patients. Here, we report on a case 
      of infiltrating lobular carcinoma of the breast with metastases to the bone. 
      Histopathologic analysis showed that the patient was estrogen and progesterone 
      receptor positive and human epidermal growth factor-2 negative. This case 
      represents the clinical spectrum of complications caused by metastasis: the 
      patient experienced a considerable amount of skeletal-related complications, had 
      previously received chemotherapy, and experienced disease progression while 
      taking nonsteroidal aromatase inhibitors. After treatment with oral everolimus 10 
      mg daily plus oral exemestane 25 mg daily, the patient's disease was ameliorated. 
      Combination therapy was well tolerated, with minimal adverse effects that were 
      manageable with concomitant medications. Although further analyses in larger 
      populations are necessary, the addition of everolimus to exemestane might provide 
      an effective new treatment option for patients with bone metastasis.
FAU - Beck, J Thaddeus
AU  - Beck JT
AD  - Highlands Oncology Group, Fayetteville, Ark., USA.
FAU - Mantooth, Ryan
AU  - Mantooth R
AD  - Highlands Oncology Group, Fayetteville, Ark., USA.
LA  - eng
PT  - Case Reports
DEP - 20150221
PL  - Switzerland
TA  - Case Rep Oncol
JT  - Case reports in oncology
JID - 101517601
PMC - PMC4361907
OTO - NOTNLM
OT  - Advanced breast cancer
OT  - Everolimus
OT  - Hormone receptor
EDAT- 2015/04/08 06:00
MHDA- 2015/04/08 06:01
PMCR- 2015/02/21
CRDT- 2015/04/08 06:00
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2015/04/08 06:01 [medline]
PHST- 2015/02/21 00:00 [pmc-release]
AID - cro-0008-0101 [pii]
AID - 10.1159/000375119 [doi]
PST - epublish
SO  - Case Rep Oncol. 2015 Feb 21;8(1):101-5. doi: 10.1159/000375119. eCollection 2015 
      Jan-Apr.